The management of early-stage and metastatic triple-negative breast cancer: a review.
about
Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell linesPreferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber 'cell highways'Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapyDevelopment of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapyIntrinsic cellular signaling mechanisms determine the sensitivity of cancer cells to virus-induced apoptosis.Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.Breast cancer under age 40: a different approach.MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?Calcitonin gene-related peptide inhibits osteolytic factors induced by osteoblast in co-culture system with breast cancer.Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery.Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
P2860
Q28542814-D4C0FF08-BD2F-4D5F-89F1-CAE772FFFA3AQ30599338-443DCF41-AC83-4297-A496-0D2F433A8142Q33940740-0503E347-BB62-4CE2-BAA1-9BB682883266Q34468621-B328A23B-94A7-4E34-923E-5DC5FC3801AFQ35550054-1107E8B2-DC34-45A5-B601-4D36331321ACQ37362715-AB53E704-42AA-478A-8088-91336BFE2D01Q37416907-40EBC0AA-2FB4-45A9-BF87-B1538A6BC5EDQ37709275-2ED98D81-B592-4741-8BBC-017C16091EF1Q38386346-97FED3E1-DFA7-47FC-A197-46AA0B985DEEQ38733113-11B89412-80BC-467A-9F85-6FC205761556Q38746991-17D0D2BE-BC74-4AFA-9D83-0C0891976EF2Q38992592-7A4333CB-F6FB-4FC9-8B60-2AB710277066Q41489984-5A626CF4-AD11-4B2B-B3C1-F0757608668DQ47927802-240825AD-A149-4428-80D2-939E5B44A2B8Q48222816-EC8E4521-EDDC-499E-BEDF-60B709817EDCQ48336537-D47FA1AC-2097-42CD-8FB2-C4032B24DCD1Q49547342-4FB9A43A-661A-4E75-953C-ADC5725995BBQ50268380-5D1F080D-D104-4332-8980-1064100EB76CQ55561847-E6F35BB4-59E6-4FAB-882A-A801CCDDEC71
P2860
The management of early-stage and metastatic triple-negative breast cancer: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The management of early-stage and metastatic triple-negative breast cancer: a review.
@en
The management of early-stage and metastatic triple-negative breast cancer: a review.
@nl
type
label
The management of early-stage and metastatic triple-negative breast cancer: a review.
@en
The management of early-stage and metastatic triple-negative breast cancer: a review.
@nl
prefLabel
The management of early-stage and metastatic triple-negative breast cancer: a review.
@en
The management of early-stage and metastatic triple-negative breast cancer: a review.
@nl
P2093
P2860
P1476
The management of early-stage and metastatic triple-negative breast cancer: a review.
@en
P2093
Carey K Anders
Lisa A Carey
Timothy M Zagar
P2860
P304
737-49, viii
P356
10.1016/J.HOC.2013.05.003
P577
2013-06-18T00:00:00Z